Impact of Exercise and Weight Loss on Breast Cancer Lymphedema Outcomes

Lymphedema is a common complication of curative breast cancer treatment, occurring in as many as 50% of patients undergoing axillary lymph node dissection. Because lymphedema occurs more commonly in patients with excess body weight, current guidelines recommend weight loss and home-based exercise as a strategy to manage breast cancer-related lymphedema. However, this recommendation has not […]

Read More

New Guidelines on Management of Venous Thromboembolism

Cancer patients are significantly more likely to develop venous thromboembolism (VTE) than people without cancer. Appropriate risk assessment, prophylaxis, and management of VTEs is essential to prevent the long-term complications and risk of death from deep vein thrombosis and pulmonary embolism. In a new Clinical Practice Guideline released by the American Society for Clinical Oncology […]

Read More

Antidepressants Linked to Reduced Cancer Mortality

Patients with cancer often experience depression and anxiety, and these comorbid conditions are independent risk factors for premature mortality. Many patients with cancer take antidepressants to manage these conditions, but little is known about the link between antidepressant use and mortality in patients with cancer. To evaluate this, a large, nationwide, 4-year historical cohort study […]

Read More

Nivolumab Associated With Long-Term Survival in Multiple Tumors

Immunotherapy targeting the PD-1/PD-L1 axis has become a standard component of care across multiple tumor types, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), and others. While these agents result in durable responses, there is limited data regarding long-term survival in these patients. In a secondary analysis of the phase I CA209-003 […]

Read More

fda-approvals-june-2019

New Cancer Treatments Approved in July

Selinexor, a New Treatment for Multiple Myeloma. The United States Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio®, Karyopharm Therapeutics) in combination with dexamethasone for patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies, including 2 proteasome inhibitors, 2 immunomodulatory agents, and a CD38-targeted monoclonal antibody. This approval […]

Read More

Erdafitinib Improves Outcomes in Progressive Advanced Bladder Cancer

The current standard of care for the majority of patients with advanced urothelial carcinoma includes cisplatin-based chemotherapy followed by immunotherapy with a PD-1 or PD-L1 inhibitor. While this treatment approach is highly effective in some patients, the majority of patients do not respond to immunotherapy and treatment options for these patients are extremely limited. As […]

Read More